Indications And Dose
Susceptible infections due to Gram-positive and Gram- negative bacteria ▶BY MOUTH ▶Child 3 months–1 year: 10 mg/kg twice daily (max. per dose 125 mg) ▶Child 2–11 years: 15 mg/kg twice daily (max. per dose 250 mg) ▶Child 12–17 years: 250 mg twice daily, dose may be doubled in severe lower respiratory-tract infections or if pneumonia is suspected ▶Adult: 250 mg twice daily, dose may be doubled in severe lower respiratory-tract infections or if pneumonia is suspected ▶BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION, OR BY INTRAMUSCULAR INJECTION ▶Child: 20 mg/kg every 8 hours (max. per dose 750 mg); increased to 50–60 mg/kg every 6–8 hours (max. per dose 1.5 g), increased dose used for severe infection and cystic fibrosis ▶Adult: 750 mg every 6–8 hours; increased if necessary up to 1.5 g every 6–8 hours, increased dose used for severe infections Cellulitis | Erysipelas ▶BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION ▶Child: 20 mg/kg every 8 hours (max. per dose 750 mg); increased if necessary up to 50–60 mg/kg every 6–8 hours (max. per dose 1.5 g) ▶Adult: 750 mg every 6–8 hours; increased if necessary up to 1.5 g every 6–8 hours Acute diverticulitis [in combination with metronidazole] ▶BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION ▶Adult: 750 mg every 6–8 hours; increased if necessary up to 1.5 g every 6–8 hours, use increased dose in severe infection Lyme disease ▶BY MOUTH ▶Child 3 months–11 years: 15 mg/kg twice daily (max. per dose 500 mg) for 14–21 days (for 28 days in Lyme arthritis) ▶Child 12–17 years: 500 mg twice daily for 14–21 days (for continued → 28 days in Lyme arthritis) ▶Adult: 500 mg twice daily for 14–21 days (for 28 days in Lyme arthritis) Surgical prophylaxis ▶INITIALLY BY INTRAVENOUS INJECTION ▶Adult: 1.5 g, to be administered up to 30 minutes before the procedure, then (by intravenous injection or by intramuscular injection) 750 mg every 8 hours if required for up to 3 doses (in high risk procedures) Infection Open fractures, prophylaxis ▶BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION ▶Adult: 1.5 g every 8 hours until soft tissue closure (maximum duration 72 hours) Acute prostatitis ▶BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION ▶Adult: 1.5 g every 6–8 hours Urinary-tract infection (lower) ▶BY MOUTH ▶Child (body-weight up to 40 kg): 15 mg/kg twice daily (max. per dose 250 mg) ▶Child (body-weight 40 kg and above): 250 mg twice daily ▶Adult: 250 mg twice daily Urinary tract infection (catheter-associated) ▶BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION ▶Child 3 months–15 years: 20 mg/kg every 8 hours (max. per dose 750 mg); increased to 50–60 mg/kg every 6–8 hours (max. per dose 1.5 g), increased dose used for severe infection ▶Child 16–17 years: 0.75–1.5 g every 6–8 hours ▶Adult: 0.75–1.5 g every 6–8 hours Acute pyelonephritis ▶BY MOUTH ▶Child (body-weight up to 40 kg): 15 mg/kg twice daily (max. per dose 250 mg) ▶Child (body-weight 40 kg and above): 250 mg twice daily ▶Adult: 250 mg twice daily ▶BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION ▶Child 3 months–15 years: 20 mg/kg every 8 hours (max. per dose 750 mg); increased to 50–60 mg/kg every 6–8 hours (max. per dose 1.5 g), increased dose used for severe infection ▶Child 16–17 years: 0.75–1.5 g every 6–8 hours ▶Adult: 0.75–1.5 g every 6–8 hours l UNLICENSED USE ▶In children g Cefuroxime is used for the treatment of cellulitis, h but the dose increase is not licensed for this indication. g Cefuroxime is used for the treatment of erysipelas, h but the dose increase is not licensed for this indication. Not licensed for treatment of Lyme disease in children under 12 years. ▶Duration of treatment in Lyme disease is unlicensed.
PDF pages 575, 576